Adamas Pharmaceuticals reported 88.8M in Cash and Equivalent for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US $ 266.96M 37.53M
Acorda Therapeutics ACOR:US $ 45.71M 71.06M
Adamas Pharmaceuticals ADMS:US 88.8M 36.03M
Aerie Pharmaceuticals AERI:US $ 79.96M 42.74M
Aptinyx Inc APTX:US $ 129.23M 17.58M
Biocryst Pharmaceuticals BCRX:US $ 218.43M 8.47M
Flexion Therapeutics FLXN:US $ 107.63M 8.92M
GlaxoSmithKline GSK:LN 3503M 1254M
Glaxosmithkline GSK:US $ 3503M 1254M
Gw Pharmaceuticals GWPH:US $ 458.1M 28.65M
Heron Therapeutics HRTX:US $ 191.17M 131.43M
Intra Cellular Therapies ITCI:US $ 121.03M 8.95M
Marinus Pharmaceuticals MRNS:US $ 112.49M 10.98M
Neurocrine Biosciences NBIX:US $ 368M 15.4M
Novartis NOVN:VX SF 5117M 1316M
Omeros OMER:US $ 12.7M 3.67M
Prothena PRTA:US $ 399.83M 56.84M
Revance Therapeutics RVNC:US $ 167.63M 81.79M
Teva Pharmaceutical TEVA:IT 2.44B 693M
Zogenix ZGNX:US $ 77.33M 38.36M